This phase II trial is evaluating the use of two targeted therapies (Capmatinib and Pembrolizumab) in comparison to one targeted therapy (Pembrolizumab) to treat locally advanced or metastatic non-small cell lung cancer.
This trial is treating patients with locally advanced or metastatic non-small cell lung cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- Your cancer has not spread to other parts of the body.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A randomised, open label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumb versus pembrolizumab alone as a first line treatment for locally advanced or metastatic non-small cell lung cancer with PD-L1 ≥ 50%
Commercial Sponsor
Novartis Pharmaceuticals
Summary
For patients to be eligible to participate in this trial the non-small cell carcinoma needs to have PD-L1 expression of ≥ 50% and have no EGFR mutation or ALK rearrangement.
Eligible patients will either receive oral tablets of Capmatinib to be taken twice per day and intravenous infusion of Pembrolizumab once every 3 weeks, or 3 weekly infusions of Pembroliumab only.
Not Recruiting Hospitals Read More